IQVIA Holdings SG&A Expenses 2011-2024 | IQV

IQVIA Holdings sg&a expenses for the twelve months ending December 31, 2024 were $1.992B, a 2.97% decline year-over-year.

  • IQVIA Holdings annual sg&a expenses for 2024 were $1.992B, a 2.97% decline from 2023.
  • IQVIA Holdings annual sg&a expenses for 2023 were $2.053B, a 0.87% decline from 2022.
  • IQVIA Holdings annual sg&a expenses for 2022 were $2.071B, a 5.45% increase from 2021.

IQVIA Holdings SG&A Expenses 2011-2024 | IQV

  • IQVIA Holdings annual sg&a expenses for 2024 were $1.992B, a 2.97% decline from 2023.
  • IQVIA Holdings annual sg&a expenses for 2023 were $2.053B, a 0.87% decline from 2022.
  • IQVIA Holdings annual sg&a expenses for 2022 were $2.071B, a 5.45% increase from 2021.
Related Stocks
Company NameMarket
Cap
Intuitive Surgical (ISRG)$216B
Thermo Fisher Scientific (TMO)$205.7B
Alcon (ALC)$44.2B
Edwards Lifesciences (EW)$44.1B
IDEXX Laboratories (IDXX)$37.1B
DexCom (DXCM)$34.9B
Mettler-Toledo (MTD)$27.3B
Waters (WAT)$22.6B
STERIS (STE)$21.7B
SONOVA HOLDING (SONVY)$19.3B
Hologic (HOLX)$14.4B
Fresenius Medical Care AG KGaA (FMS)$13.5B
Penumbra (PEN)$11.7B
Sysmex ADR (SSMXY)$11.5B
Globus Medical (GMED)$11.5B
Masimo (MASI)$9.5B
Glaukos (GKOS)$8.7B
Teleflex (TFX)$8.1B
Inari Medical (NARI)$4.7B
Integer Holdings (ITGR)$4.5B
PROCEPT BioRobotics (PRCT)$3.4B
Veracyte (VCYT)$3.2B
Nihon Kohden (NHNKY)$2.7B
LivaNova (LIVN)$2.6B
TransMedics (TMDX)$2.5B
Elekta AB (EKTAY)$2.3B
Tandem Diabetes Care (TNDM)$2.1B
Integra LifeSciences Holdings (IART)$1.7B
Alphatec Holdings (ATEC)$1.5B
Pulse Biosciences (PLSE)$1.2B